U.S. markets open in 4 hours 17 minutes

IGM Biosciences, Inc. (IGMS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
74.82+4.30 (+6.10%)
At close: 4:00PM EDT

IGM Biosciences, Inc.

325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873
http://igmbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees144

Key Executives

NameTitlePayExercisedYear Born
Mr. Fred M. SchwarzerCEO, Pres & Director847.52kN/A1953
Dr. Bruce A. KeytChief Scientific Officer636.33kN/A1953
Dr. Shinyu Chen M.D., Ph.D.Consultant675.25kN/A1969
Mr. Misbah TahirChief Financial OfficerN/AN/A1975
Mr. Paul C. GraffagninoVP of Legal AffairsN/AN/AN/A
Ms. Suzette TauberChief HR OfficerN/AN/A1964
Dr. Angus M. Sinclair Ph.D.Sr. VP of Immuno-OncologyN/AN/AN/A
Dr. Lisa L. Decker Ph.D.Chief Bus. OfficerN/AN/A1969
Mr. George A. GauthierChief Commercial OfficerN/AN/A1972
Mr. Marvin S. Peterson Ph.D.Sr. VP, Process Sciences & ManufacturingN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Corporate Governance

IGM Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 8; Board: 5; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.